US경제·CNBC Business RSS· 번역 중

AI가 열심히 번역 중이에요 🤖

곧 한글 번역본을 제공해드릴게요. 잠시만 기다려주세요!

CVS blows past estimates, hikes guidance as insurance unit continues to improve

CVS blows past estimates, hikes guidance as insurance unit continues to improve

2026.08.05 23:15
AI 감성 분석
롱 (매수 신호)
롱 66%숏 34%

CVS의 강력한 실적 개선과 가이던스 상향, 그리고 엘리리리(Eli Lilly)와의 전략적 파트너십은 주가에 상당한 상승 모멘텀을 시사합니다.

핵심 요약

CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.

CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.

Original Article

CVS blows past estimates, hikes guidance as insurance unit continues to improve

CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.

Source: https://www.cnbc.com/2026/08/05/cvs-health-cvs-earnings-q2-2026.html

주린이 포트폴리오 © 2026

본 정보는 투자 조언이 아닙니다. 매매 결정과 책임은 사용자 본인에게 있습니다.